TLK vs BBIO Comparison

PT Telkom Indonesia (Persero) Tbk is the integrated telecommunications provider in Indonesia. It also provides a wide range of other communication services, including telephone network, interconnection services, multimedia, data and internet communication-related services, satellite transponder leasing, leased line, intelligent network and related services, cable television, and VoIP services. It derives revenue from product lines: Mobile, Consumer, Enterprise, WIB, and Others. The firm has identified five reportable segments, namely B2C, B2B Infra, B2B ICT, International, and Others. The firm generates the majority of its revenue from the B2C segment.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.